{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:18:35Z","timestamp":1792664315215,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.taap.2020.115035","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T02:35:54Z","timestamp":1588905354000},"page":"115035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Cholecystokinin-1 receptor agonist induced pathological findings in the exocrine pancreas of non-human primates"],"prefix":"10.1016","volume":"399","author":[{"given":"Niels Chresten Berg","family":"Nyborg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke Kaae","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sietske","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Wederkinck","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5885-4541","authenticated-orcid":false,"given":"Anne","family":"Bugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte Schjellerup","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Thorup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-7499","authenticated-orcid":false,"given":"Trine Ryberg","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2020.115035_bb0005","first-page":"R1149","article-title":"Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans","volume":"280","author":"Beglinger","year":"2001","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"key":"10.1016\/j.taap.2020.115035_bb0010","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0006-8993(01)02468-4","article-title":"Expression and regulation of cholecystokinin and cholecystokinin receptors in rat nodose and dorsal root ganglia","volume":"903","author":"Broberger","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.taap.2020.115035_bb0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejphar.2018.06.020","article-title":"Cloning and characterization of the porcine gastrin\/cholecystokinin type 2 receptor","volume":"833","author":"Bugge","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2020.115035_bb0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41366-019-0386-0","article-title":"Long-acting CCK analogue NN9056 lowers food intake and body weight in obese G\u00f6ttingen Minipigs","volume":"44","author":"Christoffersen","year":"2020","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.taap.2020.115035_bb0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/01926230490268756","article-title":"Best practices guideline: toxicologic histopathology","volume":"32","author":"Crissman","year":"2004","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2020.115035_bb0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1152\/physrev.00014.2005","article-title":"Cholecystokinin and gastrin receptors","volume":"86","author":"Dufresne","year":"2006","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.taap.2020.115035_bb0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0940-2993(11)80157-0","article-title":"IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassay","volume":"44","author":"Faccini","year":"1992","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.taap.2020.115035_bb0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1293\/tox.25.215","article-title":"Histopathological changes in the pancreas from a spontaneous hyperglycemic cynomolgus monkey","volume":"25","author":"Fujisawa","year":"2012","journal-title":"J. Toxicol. Pathol."},{"key":"10.1016\/j.taap.2020.115035_bb0045","doi-asserted-by":"crossref","first-page":"G507","DOI":"10.1152\/ajpgi.2001.281.2.G507","article-title":"Molecular characterization and organ distribution of type A and B cholecystokinin receptors in cynomolgus monkey","volume":"281","author":"Holicky","year":"2001","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.taap.2020.115035_bb0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/0192623311406288","article-title":"Unbiased histological examinations in toxicological experiments (or, the informed leading the blinded examination)","volume":"39","author":"Holland","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2020.115035_bb0055","series-title":"M3(R2) Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals","author":"ICH","year":"2009"},{"key":"10.1016\/j.taap.2020.115035_bb0060","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1053\/gast.2001.29557","article-title":"Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin","volume":"121","author":"Ji","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.taap.2020.115035_bb0065","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1034\/j.1600-0773.2002.910610.x","article-title":"Human pancreatic acinar cells do not respond to cholecystokinin","volume":"91","author":"Ji","year":"2002","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.taap.2020.115035_bb0070","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.clpt.6100272","article-title":"Stimulation of cholecystokinin-a receptors with GI181771X does not cause weight loss in overweight or obese patients","volume":"83","author":"Jordan","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2020.115035_bb0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.clpt.6100272","article-title":"Stimulation of cholecystokinin-a receptors with GI181771X does not cause weight loss in overweight or obese patients","volume":"83","author":"Jordan","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2020.115035_bb0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00418-014-1281-3","article-title":"Cellular and subcellular localization of cholecystokinin (CCK)-1 receptors in the pancreas, gallbladder, and stomach of mice","volume":"143","author":"Konno","year":"2015","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.taap.2020.115035_bb0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0167-0115(93)90410-A","article-title":"Effects of a physiological dose of cholecystokinin on food intake and postprandial satiation in man","volume":"43","author":"Lieverse","year":"1993","journal-title":"Regul. Pept."},{"key":"10.1016\/j.taap.2020.115035_bb0090","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.taap.2020.115035_bb0095","series-title":"UK GLP Legislation - Medicines and Healthcare products Regulatory Agency","author":"MHRA","year":"1999"},{"key":"10.1016\/j.taap.2020.115035_bb0100","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0306-4522(96)00675-6","article-title":"Characterization of cholecystokininA and cholecystokininB receptors expressed by vagal afferent neurons","volume":"79","author":"Moriarty","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.taap.2020.115035_bb0105","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1159\/000324279","article-title":"New advances in cell physiology and pathophysiology of the exocrine pancreas","volume":"28","author":"Mossner","year":"2010","journal-title":"Dig. Dis."},{"key":"10.1016\/j.taap.2020.115035_bb0110","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/0192623313506792","article-title":"Species- and dose-specific pancreatic responses and progression in single- and repeat-dose studies with GI181771X: a novel cholecystokinin 1 receptor agonist in mice, rats, and monkeys","volume":"42","author":"Myer","year":"2014","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2020.115035_bb0115","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0031-6997(24)01427-3","article-title":"International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors","volume":"51","author":"Noble","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.taap.2020.115035_bb0120","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2337\/db11-0936","article-title":"The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species","volume":"61","author":"Nyborg","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.taap.2020.115035_bb0125","series-title":"OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring ENV\/MC\/CHEM(98)17","author":"OECD","year":"1998"},{"key":"10.1016\/j.taap.2020.115035_bb0130","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0031-9384(82)90230-X","article-title":"C-terminal octapeptide of cholecystokinin decreases food intake in obese men","volume":"29","author":"Pi-Sunyer","year":"1982","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.taap.2020.115035_bb0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0016-5085(03)00697-8","article-title":"Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue","volume":"125","author":"Reubi","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.taap.2020.115035_bb0140","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1242\/dmm.009621","article-title":"Anti-obesity drugs: past, present and future","volume":"5","author":"Rodgers","year":"2012","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.taap.2020.115035_bb0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev.physiol.69.031905.161253","article-title":"Why does pancreatic overstimulation cause pancreatitis?","volume":"69","author":"Saluja","year":"2007","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.taap.2020.115035_bb0150","first-page":"53","article-title":"Effect of CCK on food intake in man: physiological or pharmacological effect?","volume":"29","author":"Schick","year":"1991","journal-title":"Z. Gastroenterol."},{"key":"10.1016\/j.taap.2020.115035_bb0155","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1749-6632.1994.tb44067.x","article-title":"Role of CCK in gallbladder function","volume":"713","author":"Schjoldager","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.taap.2020.115035_bb0160","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1021\/acs.jmedchem.8b01558","article-title":"Structure-activity relationships and characterization of highly selective, long acting, peptide-based cholecystokinin 1 receptor (CCK-1R) agonists","volume":"62","author":"Sensfuss","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.taap.2020.115035_bb0165","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2337\/dc16-2684","article-title":"Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight\/obesity and Normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.taap.2020.115035_bb0170","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2174\/1568026033452258","article-title":"CCK1R agonists: a promising target for the pharmacological treatment of obesity","volume":"3","author":"Szewczyk","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.taap.2020.115035_bb0175","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1006\/rtph.1994.1013","article-title":"Tumor incidence in a chemical carcinogenesis study of nonhuman primates","volume":"19","author":"Thorgeirsson","year":"1994","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.taap.2020.115035_bb0180","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1093\/carcin\/bgl090","article-title":"Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human ha-ras oncogene in rat pancreas","volume":"27","author":"Ueda","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.taap.2020.115035_bb0185","series-title":"Guidelines on the Quality, Safety, and Efficacy of Biotherapeutic Protein Products Prepared by Recombinant DNA Technology","author":"WHO","year":"2013"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20301599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20301599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:50:16Z","timestamp":1758574216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X20301599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":37,"alternative-id":["S0041008X20301599"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2020.115035","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholecystokinin-1 receptor agonist induced pathological findings in the exocrine pancreas of non-human primates","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2020.115035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115035"}}